Loading
Transcode Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Dudley Robert Michael, was filed 02 Oct 2023.
Transcode Therapeutics, Inc.: what insiders have been doing
Transcode Therapeutics, Inc. belongs to the Health Care sector. Filings by its managers are published through SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 2 filings came from 1 insider.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Insider buying of Transcode Therapeutics, Inc. has been absent for the past year.
For context, the typical company on the same exchange (median of 5,814 companies) published 19 filings over the same period, against 2 filings here. The full history, which starts in 2022, counts 7 purchases against no sales.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
9
Thresholds
n/a
Buy Volume
€220,810
7 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- -89.3%Entry US$909,216.00 · Close at T+365 US$97,574.40
- -89.0%Entry US$1,330,560.00 · Close at T+365 US$145,992.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.80
Analyst consensus
Income statement
EBITDA-US$34.3M
Net income-US$34.7M0.0% margin
Valuation
P/Book1.5x
Beta1.26
Balance sheet & cash
Market capUS$30.5M
Free Cash Flow-US$19.5M
Debt / Equity0%
Profitability & ownership
ROE-59.3%
ROA-19.9%
% insiders1.8%
% institutions0.4%
Last declaration on 5 August 2026
Declarations9 total
49,350 shares@ US$0.5162.3% of flowCommon StockSEC:0001104659-23-105925:0
Canonical exit: 27 Dec 2023 (T+90)
98,000 shares@ US$0.5125.9% of flowCommon StockSEC:0001104659-23-105924:0
Canonical exit: 27 Dec 2023 (T+90)
6,607 shares@ US$2.54988.5% of flowCommon StockSEC:0001104659-23-073872:0
Canonical exit: 18 Sept 2023 (T+90)
19,000 shares@ US$2.7626.6% of flowCommon StockSEC:0001104659-23-070804:0
Canonical exit: 7 Sept 2023 (T+90)
20,000 shares@ US$1.1512.6% of flowCommon StockSEC:0001104659-22-100931:0
Canonical exit: 13 Dec 2022 (T+90)
12,000 shares@ US$1.2737.7% of flowCommon StockSEC:0001104659-22-072369:0
Canonical exit: 14 Sept 2022 (T+90)
28,000 shares@ US$1.844426.4% of flowCommon StockSEC:0001104659-22-067099:0
Canonical exit: 25 Aug 2022 (T+90)
9 of 9 declarations
About Transcode Therapeutics, Inc.
Transcode Therapeutics, Inc. is a company focused on developing innovative therapies for cancer treatment. It specializes in RNA-based solutions to enhance patient outcomes.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
